By Fineline Cube 
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with its equity-affiliated company Beijing Protein Innovation Co., Ltd. The deal secures all related technologies for the NeoAB33 novel drug project for a total consideration of RMB20 million (USD 2.6 million).
Transaction Details
The agreement encompasses the design, modification, and production technologies for the protein linked to research code NeoAB33. This Category 1 biological product is under development for treating acute ischemic stroke (AIS) and microcirculation disorders. These disorders include diabetes-induced nephropathy, peripheral neuropathy, retinopathy/ocular fundus diseases, and as adjuvant therapy for hypertension.
Drug Mechanism
The protein can release bradykinin and lysine bradykinin from kininogen. It promotes blood flow through immediate vasodilation and long-term angiogenesis, increasing blood flow to various tissues such as the brain, kidney, and heart. It also activates downstream pathways to perform physiological functions like dilating capillaries, relaxing vascular smooth muscle, increasing blood flow, lowering blood pressure, anticoagulation, thrombolysis, and reducing blood viscosity.-Fineline Info & Tech